Home/Pipeline/Cannabinoid-based Therapy

Cannabinoid-based Therapy

Parkinson's Disease

PreclinicalPartnered for First-in-Human Trial

Key Facts

Indication

Parkinson's Disease

Phase

Preclinical

Status

Partnered for First-in-Human Trial

Company

Gb Sciences

About Gb Sciences

Gb Sciences is a Las Vegas-based biopharmaceutical company founded in 2009 with a mission to bridge botanical medicine and modern drug discovery. Its core strategy utilizes the AI-powered PhAROS platform to deconvolute plant mixtures into defined, synergistic drug candidates. The company's key achievement is a patented, cannabinoid-based Parkinson's disease therapy with positive animal proof-of-concept data, now partnered for first-in-human trial sponsorship, alongside a broader preclinical pipeline.

View full company profile

Therapeutic Areas

Neurology Inflammation/Immunology Cardiology

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active